

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/12.	A1	(11) International Publication Number: WO 97/48389 (43) International Publication Date: 24 December 1997 (24.12.97)
<p>(21) International Application Number: PCT/EP97/03185</p> <p>(22) International Filing Date: 18 June 1997 (18.06.97)</p> <p>(30) Priority Data: RM96A000430 18 June 1996 (18.06.96) IT</p> <p>(71) Applicant (for all designated States except US): CONSIGLIO NAZIONALE DELLE RICERCHE [IT/IT]; Piazzale Aldo Moro, 7, I-00185 Roma (IT).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): AMICI, Carla [IT/IT]; Via Panaro, 11, I-00199 Roma (IT). ELIA, Giuliano [IT/IT]; Via della Stella, 321, I-00036 Palestrina (IT). GARACI, Enrico [IT/IT]; Via Salaria, 237, I-00199 Roma (IT). ROSSI, Antonio [IT/IT]; Via Orientale, 33, I-66010 Colledara (IT). SANTORO, Maria, Gabriella [IT/IT]; Via Vasto, 8, I-83100 Avellino (IT).</p> <p>(74) Agent: GERVASI, Gemma; Notarbartolo & Gervasi, Corso di Porta Vittoria, 9, I-20122 Milan (IT).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: 2-CYCLOPENTEN-1-ONE AS AN INDUCER OF HSP70</p>		
<p>(57) Abstract</p> <p>The invention relates to 2-cyclopenten-1-one as an inducer of the heat shock protein HSP70 by activating the heat shock transcription factor HSF, and selectively inducing the transcription and translation of HSP70 in human cells. In particular, since a cytoprotective role of HSP70 during viral infection was previously shown, the invention refers to 2-cyclopenten-1-one and its pharmaceutically acceptable derivatives as inducers of HSP70 with antiviral activity. Treatment with 2-cyclopenten-1-one and its pharmaceutically acceptable derivatives causes a dose-dependent reduction of infectious virus yield during infection with vesicular stomatitis virus. The block of virus replication is due to inhibition of viral protein synthesis, associated with HSP70 synthesis.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NF	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NI	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

2-CYCLOPENTEN-1-ONE AS AN INDUCER OF HSP70

FIELD OF THE INVENTION

The present invention relates to 2-cyclopenten-1-one as an inducer of HSP70. In particular the invention relates to 2-cyclopenten-1-one and its pharmaceutically acceptable derivatives as inducers of HSP70 with
5 antiviral activity.

BACKGROUND

As known, prostaglandins (PGs) are a class of naturally occurring cyclic 20-carbon fatty acids that are syntetized by various kinds of eukaryotic cells in response to external stimuli and play an important
10 role in the physiological response to cell proliferation and differentiation. Since their discovery, they were shown to function as microenvironmental hormones and intracellular signal mediators and to control a large number of physiological and pathological processes, including cell proliferation and differentiation, immune response,
15 inflammation, cytoprotection and the febrile response.

In particular, the type A and J PGs, which posses a cyclopentenonic structure, are strong inhibitors of virus replication ("Stress Proteins: Induction and Function" Schlesinger MJ, Garaci E., Santoro M.G. ed.s, Springer-Verlag, Heidelberg-Berlin, 27-44, 1990).

20 Stress proteins, also called Heat Shock Proteins (HSPs) (Proc. Natl. Acad. Sci. USA 86, 8407-8411, 1989) are a family of polypeptides synthetized by eukaryotic and prokariotyc cells in response to a heat shock or other kinds of environmental stress. The HSPs are encoded by a cellular subgroup of genes, identified as stress genes.

25 The cytoprotective role of the stress proteins has been described in

- 2 -

numerous pathologies, among which ischemia (M.S. Marber et al., J. Clin. Invest. 93, march 1994, 1087-1094).

The authors have shown that some cyclopentenonic prostaglandins (PGA e PGJ) induce the synthesis of heat shock protein HSP70 in human cells
5 through the activation of the heat shock transcription factor HSF (C. Amici et al., Proc. Natl. Sci. USA vol. 89, 6227-6231, 7 1992)

It is also known that, in the pathogenesis of the viral infection, the stress proteins HSP interfere at various levels with the virus replication, and in particular a cytoprotective role of the HSP70
10 protein has been characterized in some experimental models of acute infection (M.G. Santoro, Experientia, Vol. 50, 1039-1047, 1994). The possibility to selectively activate some "heat shock" (hs) genes and to manipulate the cellular stress response to the host advantage is suggested by recent studies which demonstrate that prostaglandins are
15 able to induce HSP70 synthesis in a non-stress situation and to protect the host cell during virus infection (M.G. Santoro, Experientia, Vol. 50, 1039-1047, 1994).

The authors have recently shown that the induction of HSP70 synthesis is one of the molecular mechanisms used by cyclopentenonic
20 prostaglandins to cause a selective and reversible block of the protein synthesis in infection models with single strand negatively polarized RNA viruses (C. Amici et al., J. Virol. 68, 6890-6899, 1994).

SUMMARY OF THE INVENTION

25 It has now been found that 2-cyclopenten-1-one, the structure constituting the center nucleus of PGA and PGJ, turns out to have an activity which is analogous to PGA and PGJ, that is, it is able to

- 3 -

induce the synthesis of HSP70 protein, even though it does not contain the corresponding acid function and aliphatic lateral chains. Therefore it seems that the lateral chains, which are present in the PGA and PGJ, with their substituents and double bonds, in particular the acid function, which implies the fatty acid nature of prostaglandins, can be eliminated without substantially modifying the herein above described specific activity.

It is therefore an object of the present invention the 2-cyclopenten-1-one as inducer of HSP70.

Another object of the invention is the 2-cyclopenten-1-one as inducer of HSP70 with antiviral activity. Another object of the invention are the 2-cyclopenten-1-one pharmaceutically acceptable derivatives as inducers of HSP70 with antiviral activity.

Further objects of the invention are pharmaceutic compositions comprising 2-cyclopenten-1-one and/or its pharmaceutically acceptable derivatives to make medicaments with antiviral activity. In particular antiviral activity against single strand negatively polarized RNA viruses and DNA viruses. Further objects of the invention will be evident from the following detailed description of the invention.

BRIEF DESCRIPTION OF FIGURES

Fig. 1AI shows the kinetics of HSF (Heat Shock Factor) activation by 2-cyclopenten-1-one. Whole cell extracts were subjected to EMSA.

Fig. 1AII shows the kinetics of HSF (Heat Shock Factor) activation by 2-cyclopenten-1-one. The HSF-HSE complexes were quantitated with a Molecular Dynamics PhosphorImager (MDP).

Fig. 1BI shows the transcription rates, measured by nuclear run-on assay. Following hybridization, filters were visualized by

- 4 -

autoradiography.

Fig. 1BII shows the transcription rates, measured by nuclear run-on assay. Following hybridization, the radioactivity was quantitated by MDP analysis.

5 Fig. 1CI shows the effect of 2-cyclopenten-1-one on protein synthesis. Cells were processed for autoradiography.

Fig. 1CII shows the effect of 2-cyclopenten-1-one on protein synthesis. HSP70 synthesis was determined by densitometric analysis of the autoradiograms.

10 Fig. 2A shows the effect of 2-cyclopenten-1-one on VSV replication. The VSV titers are shown.

Fig. 2BI shows the effect of 2-cyclopenten-1-one on VSV protein synthesis. Uninfected cells are shown.

Fig. 2BII shows the effect of 2-cyclopenten-1-one on VSV protein
15 synthesis. VSV infected cells are shown. HSP70 is indicated by the arrow.

DETAILED DESCRIPTION OF THE INVENTION

The 2-cyclopenten-1-one is a known product, which can be synthesized according to the process described in Beilstein (*Daene, Eder, A. 539*
20 [1939] 207, 211).

According to the present invention 2-cyclopenten-1-one, preferably in concentration ranging between 100 and 500 μ M, can activate the HSF transcription factor and selectively induce the transcription and translation of the HSP70 gene. In particular, induction tests have
25 been performed on human erythroleukemia cells (K562 cells), as shown in Fig.1.

The HSP70 synthesis was detected also in other types of human cells.

- 5 -

(HEp-2, HeLa) and in monkey epithelial cells (MA104 cells) (Fig.2) treated with 2-cyclopenten-1-one. Moreover, the induction of HSP70 synthesis is found to be associated with high antiviral activity. Infact, in MA104 cells infected with the Vesicular Stomatitis Virus (VSV) (1-10P.F.U./cell) the treatment with 2-cyclopenten-1-one, started 1 hour after infection, causes a dose-dependent reduction in the production of infectious viral particles (Fig.2A). As in the case of other HSP70 inducers, the block in the replication of the virus is caused by the selective inhibition of the synthesis of viral proteins, associated with the synthesis of HSP70 protein (Fig.2B).

These results confirm the antiviral activity of 2-cyclopenten-1-one as inducer of HSP70 and show the possibility of using 2-cyclopenten-1-one to induce the synthesis of HSP70 and inhibit viral replication. Based on these results it is possible to use 2-cyclopenten-1-one, as well as its pharmaceutically acceptable derivatives, as active substances to produce medicaments, in particular medicaments having antiviral activity against negative strand RNA viruses and DNA viruses, sensitive to the antiviral activity of cyclopentenonic prostaglandins.

It is an advantage of the invention to have a product with antiviral action at low costs for its synthesis and a novel mechanism of antiviral action, different from antiviral drugs in use.

The following examples are reported to illustrate the invention. They should be considered in any case non limiting the scope of the invention itself.

The reagents used in the examples, including 2-cyclopenten-1-one, were products of Sigma Aldrich. ^{32}P e ^{35}S were produced by AMERSHAM. Fetal

- 6 -

calf serum and cellular culture media were produced by GIBCO.

EXAMPLE I

The effect of the treatment with 2-cyclopenten-1-one on the HSF activation, on the heat shock gene transcription and on the synthesis
5 of the proteins have been evaluated in K562 cells with the methods described hereinbelow and shown in Fig. 1.

KINETICS OF ACTIVATION

The cells were prepared according to the method described in C.Amici et al. Cancer Research 55, 4452-4457, 1995.

10 Whole-cell extracts, prepared at different times after treatment with 500µM of 2-cyclopenten-1-one in ethanol or after 3 hours of heat shock (45°C for 20 min) were subjected to EMSA (Electrophoretic Mobility Shift Assay) (Fig. 1AI), as described in C.Amici et al. Cancer Research 55, 4452-4457, 1995. The positions of HSF, CHBA (HFS-DNA
15 constitutive activity) and NS (proteins-DNA non-specific interaction) are indicated. The levels of HSF DNA-binding activity in cells treated with 2-cyclopente-1-one were quantitated with a Molecular Dynamics PhosphorImager (MDP) (Fig. 1AII). The HSF values were normalized to the level of HSF DNA-binding activity at 9 h after treatment, which
20 was given a value of 100%.

As evident, 2-cyclopenten-1-one is able to activate HSF. The activation is prolonged for the following 24 hours, with a maximum at 9 hours from the beginning of the treatment.

TRANSCRIPTION RATE OF HSP70 GENE.

25 The transcription rates were measured by Nuclear Run-On assay (C.Amici et al., Cancer Research 55, 4452-4457, 1995). The ³²P-labelled RNA was hybridized to nitrocellulose filters containing plasmids for the

- 7 -

following human genes: *hsp70* (pH.2.3; B.Wu et al., Mol. Cell. Biol. 5, 330 (1985)); *grp78/BiP* (glucose-regulated 78 protein) (pHG 23.1; C.Amici et al., Proc. Natl. Acad. Sci. USA 89, 6227, 1992); *hsc70* (heat shock cognate 70) (pHA 7.6; C.Amici et al., Proc. Natl. Acad. Sci. USA 89, 6227, 1992); HO (heme oxygenase) (HO clone 2/10; A.Rossi e M.G.Santoro, Biochem. J., 308, 455, 1995); *GAPDH* (rat glyceraldehyde phosphate dehydrogenase) (*GAPDH*, 1400 bp, *Pst*I; A.Rossi e M.G.Santoro, Biochem. J., 308, 455, 1995). The vector plasmid (Bluescript) was used as a non-specific hybridization control. Following hybridization, the filters were visualized by autoradiography (Fig. 1BI) and the radioactivity was quantitated by MDP analysis (Fig. 1BII). The values are expressed as arbitrary units obtained by comparing transcription rates to control levels. As evident, 2-cyclopenten-1-one is able to selectively activate the *hsp70* gene transcription. The transcription is prolonged at high levels for at least 9 hours from the beginning of the treatment.

EFFECT OF 2-CYCLOPENTEN-1-ONE ON HSP70 PROTEIN SYNTHESIS Equal amounts of protein from K562 cells labeled with [³⁵S]-methionine (10 µCi/10⁶ cells, 1 h pulse) at different times after treatment with 500 µM 2-cyclopenten-1-one were analyzed on 10% SDS/PAGE gels and processed for autoradiography (Fig. 1CI) Hsp70 synthesis (?) was determined by densitometric analysis of the autoradiograms (Fig. 1CII). Total protein synthesis (?) was determined as [³⁵S]-methionine incorporation into TCA-insoluble material (C.Amici et al., Exp. Cell. Res. 207, 230-234, 1993).

As evident, 2-cyclopenten-1-one is able to selectively stimulate HSP70 protein synthesis at concentrations that do not inhibit the cellular

- 8 -

protein synthesis.

EXAMPLE II

The effect of 2-cyclopenten-1-one on the replication of Vesicular Stomatitis Virus (VSV) and on the HSP70 protein synthesis was evaluated as described in the following and illustrated in Fig. 2.

- 5 Confluent monolayers of monkey kidney MA104 cells, grown in RPMI-1640 medium supplemented with 5% FCS (fetal calf serum) and antibiotics, were infected with VSV (Indiana serotype, Orsay; 1 P.F.U./cell). After 1 h at 37°C, the viral inoculum was removed and cells were kept at 37°C in RPMI-1640 medium containing 2% FCS and different
10 concentrations of 2-cyclopenten-1-one in ethanol or control diluent.

VSV titers were determined 24 h post infection (p.i.) by cytopathic effect 50% (CPE 50%) assay, as described in F.Pica et al., Antiviral Res., vol. 20, 193, 1993 and illustrated in Fig. 2A.

- Uninfected (U) or VSV-infected (VSV) MA104 cells were treated with 250
15 µM (lanes 2 and 5) and 500 µM (lanes 3 and 6) 2-cyclopenten-1-one, or with control diluent (lanes 1 and 4), soon after VSV infection and labeled with [³⁵S]-methionine (8 µCi/2x10⁵ cells, 1 h pulse starting 5 h p.i.). Equal amounts of protein were analyzed on 10% SDS/PAGE gel and processed for autoradiography. The position of hsp70, identified
20 by western blot analysis using anti-human hsp70 antibodies, is indicated by the arrow. VSV proteins L, G, N, NS and M are indicated.

2-cyclopenten-1-one, at concentrations ranging between 100 and 500µM, inhibits the production of VSV infectious virions from 10 to more than 1000 times with respect to the control, under the indicated
25 conditions. The inhibition is mediated by a selective block of the viral protein synthesis, combined with the induction of HSP70.

- 9 -

CLAIMS

1. 2-cyclopente-1-one as inducer of HSP70 protein.
2. 2-cyclopenten-1-one and its pharmaceutically acceptable derivatives as inducrrs of the antiviral activity of HSP70 protein.
- 5 3. 2-cyclopenten-1-one and its pharmaceutically acceptable derivatives as inducters of the antiviral activity of HSP70 protein against single strand negatively polarized RNA viruses and DNA viruses.
4. 2-cyclopenten-1-one and its pharmaceutically acceptable derivatives as inductors of the antiviral activity of HSP70 protein at
10 concentrations ranging between 100 and 500 μ M.
5. Pharmaceutical compositions comprising 2-cyclopenten-1-one and its pharmaceutically acceptable derivatives in pharmaceutically acceptable doses.
6. Use of 2-cyclopenten-1-one and its pharmaceutically acceptable
15 derivatives to make pharmaceutical compositions possessing antiviral activity.

1/2










Fig. 1

SUBSTITUTE SHEET (RULE 26)

2/2

A



B i

U

VSV

B ii




Fig.2

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

Internatio. Application No

PCT/EP 97/03185

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MARIA ET AL.: "gastric cytoprotective activity of 2-cyclopenten-1-one and related compounds" BIOLOGICAL AND PHARMACEUTICAL BULLETIN, vol. 18, no. 12, December 1995, pages 1784-1786, XP002046120 * see the whole document *	1-5
Y	---	6
Y	PARKER ET AL.: "antiviral effect of cyclopentenone prostaglandins on vesicular stomatitis virus replication" ANTIVIRAL RESEARCH, vol. 26, no. 1, January 1995, pages 83-96, XP002046121 * see in particular page 93, 2nd paragraph * --- -/--	6

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

7 November 1997

Date of mailing of the international search report

26. 11. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Insert, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/03185

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
P;X	<p>ROSSI ET AL. : "2-cyclopenten-1-one, a new inducer of heat shock protein 70 with antiviral activity"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 50, 13 December 1996, pages 32192-32196, XP002046122 * see the whole document *</p>	1-6
A	<p>SANTORO: "heat shock proteins and virus replication: HSP70S as mediators of the antiviral effects of the prostaglandins"</p> <p>EXPERIENTIA, vol. 50, no. 11-12, 1994, pages 1039-1047, XP002046123 cited in the application * see the whole document *</p>	1-6

THIS PAGE BLANK (USPTO)